CRSP - With the Market Down I'm Buying These 3 Stocks
No one can predict the future. Attempting to decipher whether yesterday's 2,013-point plunge in the Dow Jones Industrial Average was an aberration or the start of a new bear market is essentially a waste of time. What we do know for sure is that the U.S. stock markets will eventually recover. In 20 years' time, the Dow is far more likely to surpass the 50,000 mark than sink back to the 10,000 level.
A Great Depression isn't imminent, and there has been too much progress in the digital age for the economy not to regain its footing at some point soon. So, in a word, yesterday's bloodbath in the markets should turn out to be nothing more than a once-in-a-lifetime buying opportunity for investors with a long-term horizon (10 years or more).
Which stocks are now too cheap too ignore on the heels of this historic sell-off? I plan on buying these three high-growth biopharma stocks on any further weakness: Amicus Therapeutics (NASDAQ: FOLD), Amarin (NASDAQ: AMRN), and CRISPR Therapeutics (NASDAQ: CRSP). Here's why.